Exploring better strategies for EGFR antibodies in colon cancer
Mené sur 169 patients atteints d'un cancer colorectal avancé sans mutation du gène KRAS, cet essai de phase II évalue l'efficacité, du point de vue de la survie sans échec à 10 mois, et la toxicité du cetuximab en complément d'une chimiothérapie FOLFOX
Treatment of advanced colon cancer has improved over the past 15 years. Until the late 1990s, colorectal cancer was considered a chemoresistant disease, for which only fluorouracil could be offered as a palliative treatment. However, many options are available today. The combination of chemotherapy and biological drugs—including anti-EGFR or anti-VEGF antibodies—for first-line treatment, as well as the sequencing of different active drugs as disease progresses, can significantly improve outcomes...
The Lancet Oncology , commentaire en libre accès, 2013